Frazier Life Sciences Management, L.P.

Reported value$4.59Bas of Jun 30, 2026

Positions41 6 new, 3 sold out

Top 10 weight74%MIRM alone is 20%

FiledAug 1445 days after quarter end

Portfolio · as of Jun 30, 2026

Where the money is

New or addedTrimmedHeld

MIRM

Mirum Pharmaceuticals INC

19.6%

NAMS

Newamsterdam Pharma Company

ERAS

MBX

ARQT

Arcutis Biotherapeutics INC

5.6%

TRVI

Trevi Therapeutics INC

4.0%

KRYS

Krystal Biotech INC

3.9%

MAZE

Maze Therapeutics INC

3.3%Added

PHAT

Phathom Pharmaceuticals INC

2.9%

PVLA

Palvella Therapeutics INC Ne

2.9%

31 others

26.4%

Box size is the share of the fund's reported holdings. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.

What changed

Biggest moves since Mar 31, 2026

Filed Aug 14, 2026, compared with the May 15, 2026 filing

add_circleNew

PBLS $52.6M
ACHV $49.7M
DSGN $26.2M
STTK $26M

arrow_upwardAdded

ALLO +491%
Ascendis Pharma A/s +69%
AURA +39%
MNKD +12%

arrow_downwardTrimmed

BBIO −55%

remove_circleSold out

Kalvista Pharmaceuticals INC $99.9M
RVMD $65.7M
AGIO $42.5M